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ABSTRACT
Background Familial clustering of melanoma suggests 
a shared genetic predisposition among family members, 
but only 10%–40% of familial cases carry a pathogenic 
variant in a known high- risk melanoma susceptibility 
gene. We investigated whether a melanoma- specific 
Polygenic Risk Score (PRS) is associated with melanoma 
risk in patients with genetically unexplained familial 
melanoma.
Methods Dutch familial melanoma cases (n=418) 
were genotyped for 46 SNPs previously identified as 
independently associated with melanoma risk. The 
46- SNP PRS was calculated and standardised to 3423 
healthy controls (sPRS) and the association between 
PRS and melanoma risk was modelled using logistic 
regression. Within the case series, possible differences 
were further explored by investigating the PRS in relation 
to (1) the number of primary melanomas in a patient and 
(2) the extent of familial clustering of melanoma.
Results The PRS was significantly associated with 
melanoma risk, with a per- SD OR of 2.12 (95% CI 
1.90 to 2.35, p<0.001), corresponding to a 5.70- fold 
increased risk (95% CI 3.93 to 8.28) when comparing 
the top 90th to the middle 40–60th PRS percentiles. 
The mean PRS was significantly higher in cases with 
multiple primary melanomas than in cases with a single 
melanoma (sPRS 1.17 vs 0.71, p=0.001). Conversely, 
cases from high- density melanoma families had a lower 
(but non- significant) mean PRS than cases from low- 
density families (sPRS 0.60 vs 0.94, p=0.204).
Conclusion Our work underlines the significance 
of a PRS in determining melanoma susceptibility and 
encourages further exploration of the diagnostic value of 
a PRS in genetically unexplained melanoma families.
INTRODUCTION
A major environmental risk factor for cutaneous 
melanoma is a high level of intermittent ultravi-
olet radiation exposure, especially in persons with 
a fair skin type.1 2 The incidence of melanoma 
has increased in European and other Western 
countries over the last few decades,3 4 so public 
education focusing on sun protection is increas-
ingly important in preventing this potentially 
deadly disease.5 Furthermore, as up to 55% of 
melanoma risk may be attributable to genetic risk 
factors,6 people with an unfavourable genetic risk 
profile could potentially be enrolled in specific 
cancer prevention programmes. An unfavourable 
genetic risk profile may be related to phenotypic 
traits associated with melanoma risk, such as a fair 
skin type and a high number of (atypical) nevi,7 8 
but other genetic risk factors are involved in less 
readily observable processes such as DNA repair 
and cell cycle control.9 When family members share 
genetic risk factors for melanoma and (individual or 
combined) risk is sufficiently strong, familial clus-
tering of melanoma might become apparent. This 
effect has been clearly demonstrated for pathogenic 
variants in high- risk melanoma susceptibility genes 
with an autosomal dominant inheritance pattern, 
the most important of which is the cell cycle regu-
latory gene CDKN2A (MIM 600160).10 Neverthe-
less, to date only 10%–40% of familial clustering of 
melanoma can be explained by pathogenic variants 
in CDKN2A or a few other rare high- risk genes (eg, 
CDK4, POT1, BAP1).11 12
In melanoma families without identifiable vari-
ants in these high- risk genes, polygenic inheritance 
might explain melanoma risk, and a Polygenic Risk 
Score (PRS) could potentially be of considerable 
utility in a diagnostic setting.13 Rather than focusing 
on a single high- risk gene, a PRS combines the 
risk effect of a large number of common variants 
(SNPs) that have been shown to be associated with 
melanoma risk in genome- wide association studies 
(GWAS). Many of these low- risk SNPs were iden-
tified in large GWAS of patients with sporadic and 
familial melanoma, and several SNPs were found 
to be located in or near genes involved in pigmen-
tary traits, number of nevi, DNA repair or telomere 
maintenance pathways.14–17 While individual SNPs 
have only a small effect, the combined melanoma 
risk in a PRS can be substantial and might therefore 
be useful in risk stratification.18
MC1R (MIM 155555) is a well- studied gene 
carrying a number of SNPs that influence mela-
noma risk, and several of these variants are not only 
statistically associated with melanoma but also have 
a known functional role. The MC1R gene plays an 
important role in skin and hair pigmentation and 
certain variants in this gene are strongly associated 
with red hair colour (RHC variants). These variants 
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increase melanoma risk approximately twofold, whereas other 
variants less strongly associated with red hair colour (non- RHC 
variants) confer a smaller increase in melanoma risk.19 Exten-
sive research in CDKN2A- mutated families has shown that both 
RHC and non- RHC variants modify melanoma risk in these 
families,20 21 but the contribution of these variants to melanoma 
risk in non-CDKN2A melanoma families has been less well inves-
tigated. In a recent study, we observed a clear enrichment of 
MC1R risk variants (in particular RHC variants) in Dutch mela-
noma families without a pathogenic variant in CDKN2A,22 a 
finding comparable to the results of earlier studies from Sweden 
and Denmark.23 24 These findings collectively suggest an addi-
tional important role for MC1R risk variants in a non-CDKN2A 
familial melanoma setting.
In the current study, known MC1R risk variants and several 
other melanoma- associated SNPs were incorporated into a 
46- SNP PRS, and the association of this PRS with melanoma risk 
was investigated in a series of 418 Dutch patients with familial 
melanoma without a pathogenic variant in high- risk melanoma 
susceptibility genes.
METHODS
Study population
Case series
Patients with cutaneous melanoma were recruited from Clin-
ical Genetic Centres throughout the Netherlands. Patients were 
eligible for inclusion in the case series if they had at least one 
other relative (up to third- degree) with cutaneous melanoma 
and did not carry a previously identified germline mutation in 
the CDKN2A gene. Information on family history was obtained 
through detailed three- generation pedigrees drawn at the Clin-
ical Genetic Centres. Since index patient reports of melanoma 
in family members have a high known level of accuracy (true 
positive predictive value 77%–87%),25 we included in our data 
both confirmed and unconfirmed melanoma diagnoses reported 
in first- degree, second- degree and third- degree relatives. Diag-
nostic sequencing of the CDKN2A gene in the case series was 
performed at the Laboratory for Diagnostic Genome Analysis at 
the department of Clinical Genetics, Leiden University Medical 
Center. In 478 eligible cases, a multi- gene panel test including 
all known high and medium penetrance melanoma suscepti-
bility genes (CDKN2A, CDK4, BAP1, POT1, ACD, TERF2IP, 
TERT, MITF) was performed, as described previously.22 For the 
purpose of this study, we excluded patients carrying a patho-
genic germline variant in one of these genes (n=18) or patients 
with a possible non- Dutch ethnicity (determined by surname, 
n=9). To prevent oversampling of one family, only one mela-
noma case per family was included (n=33 excluded). In total, 
418 cases remained for analysis (mean age 47 years), of which 
the majority had one or two close (first- degree or second- degree) 
relatives with melanoma (54% and 34%, respectively), and 19% 
(n=80) had a personal history of more than one primary mela-
noma (table 1). Of the first- degree and second- degree relatives 
with a diagnosis of melanoma (total n=565 relatives), 54% were 
confirmed through medical records and/or pathology reports.
Control series
Healthy controls were derived from a Dutch population- based 
study called the Nijmegen Biomedical Study (n=4745).26 This 
series was originally established to obtain a universal reference 
population for different types of studies, including studies of 
genetic variation. We first assessed whether these individuals 
had complete SNP data for PRS calculation (n=32 excluded). 
Since this series is linked to the Netherlands Cancer Registry, we 
were able to exclude individuals with any type of cancer regis-
tered (n=846). After also excluding individuals under age 30 
(n=444), a total of 3423 healthy controls (mean age 57 years) 
with available SNP data remained for analysis (table 1).
SNP selection and genotyping
A total of 46 melanoma- associated SNPs derived from several 
large GWAS by the international GenoMEL consortium (https:// 
genomel. org/) were selected for this study (online supplemental 
table S1). Selection was primarily based on the significance of 
association with melanoma, and the fact that these SNPs were 
repeatedly reported and validated in independent GWAS anal-
yses.14–17 The SNPs were identified by fine- mapping of the loci 
identified in Law et al17 and using the same methodology as in 
Barrett et al.16 The samples used for fine- mapping were a subset 
of those from Law et al17 totalling 12 419 cases and 14 242 
controls (cases and controls from each centre, respectively: 
GenoMEL Phase 1: 1324, 3569, GenoMEL Phase 2: 1420, 
4046, MDACC: 1918, 1004, AMFS: 548, 430, Q- MEGA_610k: 
915, 1640, Q- MEGA_omni: 690, 553, CIDRUK: 2630, 73, 
MELARISK: 511, 815, WAMHS: 1252, 893, Essen- Heidelberg: 
1211, 1219).
To analyse the case series, we used a custom- designed targeted 
sequencing panel incorporating target- specific probes that 
selected a minimal region of 25 bp around the SNP. A custom- 
designed SNP target- specific Agilent SureSelect XT Clearseq 
enrichment kit was used for SNP genotyping, with sequencing 
based on the 200 ng XT protocol. Capture, enrichment and 
sequencing were all performed at the GenomeScan sequencing 
facility in Leiden, and sequencing was performed on the Illumina 
HiSeq4000 platform to yield 150 bp, paired- end reads. Subse-
quent data analysis was performed using an in- house pipeline to 
generate the genotype data for all SNPs per sample (a description 
of quality control procedures used while processing the geno-
type data can be found in the online supplemental material).
Control SNP data were generated using the Illumina 
HumanOmniExpress-12 and HumanOmniExpress-24 Bead-
Chip, and SNPs were imputed using the 1000 Genomes phase1 
v3 together with Genome of The Netherlands release 5 data as 
references. A detailed description of SNP genotyping, methods 
for imputation and quality control procedures in the control 
Table 1 Characteristics of the study population
Cases Controls
Number 418 3423
Sex
  Male:female 140:278 1584:1839
Age
  Mean (range) 47 (15–87) 57 (30–98)
No. of primary melanomas in case
  One (%) 338 (81) –
  Two (%) 61 (15) –
  Three or more (%) 19 (4) –
No. of first- degree or second- degree relatives 
with melanoma
  None (%)* 16 (4) –
  One (%) 226 (54) –
  Two (%) 144 (34) –
  Three or more (%) 32 (8) –
*These cases had one or more third- degree relative(s) with melanoma.
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series can be found in the online supplemental material (and has 
also been published elsewhere).26
Polygenic Risk Score
The PRS was calculated for all included individuals using the 
formula:
PRS = β1x1 + β2x2 + β3x3 + …… + β46x46
where β is the per- allele log OR for melanoma associated with 
the risk allele of the SNP, and x the number of risk alleles per SNP 
(0, 1, or 2). The ORs were the most recent estimates from the 
melanoma GWAS analyses of the GenoMEL consortium (online 
supplemental table S1).17 To facilitate comparison between the 
case and control series, the PRS was standardised (sPRS) to the 
mean and SD in the control series. The mean sPRS in population 
controls was therefore 0 with an SD of 1.
Statistical analysis
Association between PRS and melanoma risk was modelled using 
logistic regression, and reported ORs represented the OR per 
unit SD of the sPRS in the control series. The regression model 
was adjusted for age and sex. We also estimated the association 
by percentile groups of the sPRS in the control series, with the 
middle 40–60th percentile used as reference. The discrimina-
tive ability of the PRS model was assessed with Area Under the 
receiver- operating Curve (AUC) analysis. To further investigate 
possible differences in the PRS between cases with either one 
or multiple primary melanomas, we compared the mean sPRS 
between these two subgroups using the t- test for independent 
samples. We also investigated whether the extent of familial 
clustering for melanoma was correlated with the PRS using the 
Pearson correlation test. Familial clustering was quantified with 
a weighted proportion of relatives with a medical history of 
melanoma. First- degree relatives contribute with weight 0.5 and 
second- degree relatives contribute with weight 0.25. Relatives 
with multiple primary melanomas contributed with the number 
of primary melanomas they were diagnosed with. This resulted 
in the following ‘Familial Clustering Score’ (FCS):
 
FCS = Fmel∗0.5+Smel∗0.25+
(
MF−Fmel
)
∗0.5+
(
MS−Smel
)
∗0.25
Ftot∗0.5 +Stot∗0.25+
(
MF−Fmel
)
∗0.5+
(
MS−Smel
)
∗0.25  
where Ftot and Stot are the total number of first- degree and 
second- degree relatives, Fmel and Smel are the number of first- 
degree and second- degree relatives with melanoma, and MF and 
MS are the total number of primary melanomas in first- degree 
and second- degree relatives, respectively. An FCS could be calcu-
lated for a total of 369 cases (49 cases were excluded due to 
incomplete pedigree information). Using the t- test for indepen-
dent samples, we compared the mean sPRS between cases with 
the lowest 10% FCS and cases with the highest 10% FCS. These 
analyses were repeated using an alternative FCS that was based 
solely on the number of relatives with melanoma (thus ignoring 
the number of primary melanomas in a relative). We reported 
95% CIs and considered p- values statistically significant at the 
5% level (α=0.05).
RESULTS
Association between PRS and melanoma risk
On average, familial melanoma cases had a higher PRS than 
healthy controls, with a mean sPRS in the case series of 0.80 
(SD=1.14, 95% CI 0.69 to 0.91) versus the control figure set at 
0 (table 2, figure 1A). Using logistic regression, we also found 
a significant association between PRS and melanoma risk, with 
a per- SD OR of 2.12 (95% CI 1.90 to 2.35, p<0.001). The 
46- SNP PRS model had an AUC of 0.77 (95% CI 0.75 to 0.79).
After assigning the cases to percentile groups of the PRS distri-
bution determined using the control series, a significant associ-
ation was found between a PRS above the 60th percentile and 
melanoma risk (figure 2). Compared with individuals with a PRS 
in the 40–60th percentile, individuals with a PRS in the 60–80th 
percentile had an OR of 2.06 (95% CI 1.41 to 3.00) for devel-
oping melanoma, individuals in the 80- 90th percentile had an 
OR of 3.27 (95% CI 2.19 to 4.88) and individuals above the 
90th percentile had an OR of 5.70 (95% CI 3.93 to 8.28).
To further explore possible differences in the PRS for cases 
with multiple primary melanomas (n=80) and cases with a 
single melanoma (n=338), we compared the mean sPRS for 
Table 2 Descriptive analysis of the 46- SNP PRS
n
sPRS
Mean SD 95% CI
Familial melanoma cases 418 0.80 1.14 0.69 to 0.91
  No. of primary melanomas 
in case
  One 338 0.71 1.11 0.59 to 0.83
  Two or more 80 1.17 1.23 0.90 to 1.44
  Family Clustering Score
  Lowest 10% 39 0.94 1.26 0.55 to 1.33
  Middle 10%–90% 288 0.85 1.16 0.72 to 0.98
  Highest 10% 42 0.60 1.17 0.25 to 0.95
Population controls 3423 0 1 −0.03 to 0.03
PRS, Polygenic Risk Score; sPRS, standardised PRS.
Figure 1 Distribution of the standardised PRS in (A) all 418 cases 
combined (red), (B) cases divided into those with a single melanoma 
(blue) and those with multiple primary melanomas (green). Dotted lines 
correspond to the means (see table 1). PRS, Polygenic Risk Score.
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these two groups. The distributions of the sPRS for the two 
groups and the control series are displayed in figure 1B. The 
mean sPRS in cases with multiple primary melanomas (1.17, 
95% CI 0.90 to 1.44) was significantly higher than the mean 
sPRS in cases with a single melanoma (0.71, 95% CI 0.59 to 
0.83) (p=0.001). The per- SD OR for an association between 
the PRS and melanoma risk increased significantly, from 1.98 
(95% CI 1.77 to 2.22, p<0.001) for single melanoma to 
2.86 (95% CI 2.30 to 3.55, p<0.001) for multiple primary 
melanomas (p=0.003). The proportion of cases with two or 
more first- degree or second- degree relatives with melanoma 
was similar among cases with a single melanoma (42%) and 
cases with multiple primary melanomas (39%) (p=0.625), 
indicating that it is unlikely that these results were biassed by 
family history.
Additionally, we calculated an FCS for each case as described 
in the Methods section, but found no significant correlation 
between FCS and PRS (R2=0.003, Pearson correlation test: 
p=0.283). A comparison between cases with the highest 10% 
FCS (high- density melanoma families, n=42) and cases with 
the lowest 10% FCS (low- density melanoma families, n=39) 
revealed that cases from low- density melanoma families had a 
higher mean sPRS (0.94, 95% CI 0.55 to 1.33) than cases from 
high- density melanoma families (0.60, 95% CI 0.25 to 0.95) 
(table 2), although this difference did not reach statistical 
significance (p=0.204). Of note, the low- density melanoma 
families were not enriched for cases with multiple primary 
melanomas (8/39 cases (21%) had multiple primary mela-
nomas, vs 80/418 cases (19%) in the total study population; 
p=0.762), and vice versa, the high- density melanoma families 
were not enriched for cases with a single melanoma (36/42 
cases (86%) had a single melanomas, vs 338/418 cases (81%) 
in the total study population; p=0.427), so a potential bias 
related to the number of primary melanomas in these cases is 
unlikely. The distributions of the sPRSs for the three groups 
and the control series are displayed in online supplemental 
figure S1. In addition, the alternative FCS (which ignored the 
number of primary melanomas in a relative) did not show a 
significant correlation with the PRS as well (R2=0.008, Pearson 
correlation test: p=0.096). However, when compared with 
the analyses with the original FCS, an even greater difference 
in mean sPRS was observed between cases from low- density 
melanoma families (0.97, 95% CI 0.57 to 1.37) and cases from 
high- density melanoma families (0.49, 95% CI 0.13 to 0.85) 
(p=0.088), a difference principally attributable to a decrease 
in mean sPRS in high- density melanoma families (from 0.60 in 
the original FCS to 0.49 in the alternative FCS)
Analysis of the PRS in an additional 15 cases with the MITF 
p.E318K variant
In our previous multi- gene panel sequencing study, from which 
we derived the case series for the current study, we identified 15 
familial melanoma cases with the moderate penetrance variant 
c.952G>A, p.E318K (RefSeq NM_000248.3) in the MITF gene 
(MIM 156845).22 Although these 15 cases were excluded from 
the case series of the current study, PRS data were also available 
for these cases. To explore whether the PRS might be a poten-
tial modifier of melanoma risk in these families, we performed a 
descriptive analysis in this small group and found that 11 out of 
15 (73%) cases with the MITF p.E318K variant had a PRS above 
the 60th percentile of the PRS distribution, including seven 
(47%) with a PRS above the 90th percentile.
DISCUSSION
In this study, we found that a 46- SNP PRS is significantly associ-
ated with melanoma risk in a large series of familial cases ascer-
tained through Clinical Genetic Centres in the Netherlands. 
Melanoma cases had, on average, a higher PRS than healthy 
controls, and individuals in the top 90th percentile of the PRS 
were 5.7 times more likely to have melanoma compared with 
individuals in the middle 40–60th percentile. Since our familial 
cases were all previously screened for pathogenic variants in 
currently known high- risk melanoma susceptibility genes, these 
results contribute to our understanding of (poly)gen(et)ic risk in 
genetically unexplained melanoma families.
Although no previous study has specifically investigated a 
melanoma PRS in familial cases, several recent population- 
based melanoma PRS studies have reported similar findings. A 
US study reported a 1.9- fold increased melanoma risk for indi-
viduals in the highest tertile of a 21- SNP PRS compared with 
individuals in the lowest tertile.27 In another study that inves-
tigated a 45- SNP PRS that was almost identical to the PRS in 
our study, the per- SD OR was 1.75 in an Australian cohort and 
1.63 in a UK cohort.28 A third study that validated a 204- SNP 
PRS in a cohort of Southern European individuals reported a 
per- quintile OR for melanoma of 1.35, which corresponded to 
a 3.33- fold increased risk for individuals in the highest quin-
tile (>80th percentile) compared with individuals in the lowest 
quintile (<20th percentile).29 Although it is difficult to directly 
compare our results to the associations found in these studies, 
our reported per- SD OR of 2.12 seems relatively high, which 
might suggest a more important role for the PRS in a familial 
setting.
We also found that cases with multiple primary melanomas 
had a significantly higher mean PRS than cases with a single 
melanoma. The per- SD OR increased to 2.86 for multiple 
primary melanomas, providing further support for an associa-
tion between the PRS and melanoma risk. This finding indicates 
that individuals with a high PRS not only have a higher chance 
of developing melanoma but also a higher chance of developing 
subsequent melanomas. Although the development of subse-
quent tumours has not been previously investigated for mela-
noma, breast cancer PRS studies have reported similar findings, 
with bilateral breast cancer cases showing a higher PRS compared 
with unilateral breast cancer cases.30–32 Further exploration of 
Figure 2 Estimated effect sizes by percentile of the standardised PRS. 
PRS, Polygenic Risk Score; ref, reference.
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the differences in the PRS between cases with higher or lower 
numbers of multiple primary melanomas would be interesting, 
as the association might strengthen as the number of detected 
melanomas increases. As only 4% of cases in our series had three 
or more primary melanomas, these additional analyses could not 
be performed within the context of the present study. However, 
as multiple primary melanomas are not unusual in patients with 
sporadic melanoma, these analyses should be possible in larger 
population- based studies.33
To explore possible differences in PRS between cases from 
high- density versus low- density melanoma families, we calcu-
lated an FCS for each case based on the number of close family 
members with melanoma relative to the family size. Although 
the FCS and PRS were not significantly correlated in our cases, 
we did observe an inverse (non- significant) relationship between 
PRS and FCS, that is, cases with a high FCS had a relatively low 
PRS and vice versa. The inverted relationship between PRS and 
FCS became even more apparent in the analyses with the alter-
native FCS, in which we ignored the number of primary mela-
nomas in a family member. These observations might suggest that 
the PRS plays a less important role in high- density melanoma 
families. If confirmed, one possible explanation might be a still 
unidentified pathogenic variant in a (known or unknown) high- 
risk melanoma susceptibility gene or other genomic regulatory 
region that explains the strong familial clustering of melanoma, 
which often appears to follow an autosomal dominant inher-
itance pattern. This inheritance pattern is itself best reflected 
in the alternative FCS that was solely based on the number of 
relatives with melanoma, and the inverted relationship between 
PRS and FCS was indeed most obvious in analyses with the alter-
native FCS. Further studies in independent familial melanoma 
cohorts should now be performed to determine whether these 
differences can be replicated and are indeed significant.
In addition, we conducted an analysis of the PRS in carriers of 
the MITF p.E318K risk variant and found that the distribution 
of the PRS in these carriers was strongly skewed towards the 
90th percentile (47% above the 90th percentile). This observa-
tion is consistent with the hypothesis that carriers of a medium- 
penetrance risk variant like MITF p.E318K require additional 
(genetic) risk factors in order to develop melanoma,34 35 and 
suggests that a high PRS may indeed represent an additional 
risk factor. Further assessment of the PRS in a larger group of 
MITF families, including carriers without melanoma, will likely 
provide more insight into the precise relationship between 
MITF, PRS and melanoma risk.
A major strength of our study is the composition of the case 
series, as only melanoma cases with a positive family history for 
melanoma were included. Familial melanoma is likely to have a 
stronger genetic aetiology compared with sporadic melanoma, 
where environmental factors may be more important. An addi-
tional strength is the ascertainment of cases through Clinical 
Genetic Centres, facilitating the inclusion of extensive three- 
generation pedigrees for most cases (only 12% had incomplete 
pedigree information). Furthermore, the study population (both 
cases and controls) consisted entirely of Dutch individuals and 
therefore genetic variability due to ethnic differences was prob-
ably very low. Finally, our PRS model was based on a refined 
selection of 46 highly significant SNPs that have been repeatedly 
identified in large independent GWA studies.
Two limitations should be noted. First, we did not include 
traditional risk factors (eg, hair and skin colour, nevus density, 
sun exposure) in our analysis of predictive performance. None-
theless, our reported AUC of 0.77 is comparable to studies that 
included these traditional risk factors. In a study by Cust et 
al, a moderate improvement in risk prediction of 2.3% (AUC 
0.74; Australian cohort) and 2.8% (AUC 0.68; UK cohort) was 
observed after the PRS was included in a risk prediction model 
based on traditional risk factors,28 and Gu et al reported an 
improvement of 0.4% (AUC 0.89; Spanish cohort), 1.4% (AUC 
0.69; Italian cohort) and 1.9% (AUC 0.72; Greek cohort).29 
Combining a PRS with these traditional risk factors seems to 
improve the predictive capability of the model, although one 
should be aware of recall bias when including traditional risk 
factors like sun exposure and history of sunburns. A second 
possible limitation is that we developed an FCS that has not been 
scientifically evaluated as a tool to assess melanoma risk based on 
family history. However, to our knowledge no other similar tool 
is currently available for familial melanoma. Therefore, until a 
more statistically robust tool becomes available, the results from 
our FCS analysis should be interpreted with caution.
In conclusion, our findings underline the significance of the 
PRS in determining melanoma susceptibility and represent an 
important preliminary exploration of the value of a PRS in 
genetically unexplained melanoma families. The PRS had a fairly 
good ability to predict melanoma risk in our series of familial 
cases, but independent validation will be needed to confirm this 
finding. To further understand the role of the PRS in a familial 
setting, analysis of the PRS in multiple (un)affected family 
members of our cases, and including a non- familial (sporadic) 
melanoma cohort for comparison, will be necessary. A better 
understanding of genetic risk in these families may eventually 
lead to better and more personalised melanoma surveillance 
strategies.
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